Gastric MALT lymphoma: A model of chronic inflammation-induced tumor development

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 6, 2010, Pages 336-346

  Sagaert, Xavier ^a   Van Cutsem, Eric ^a   De Hertogh, Gert ^a   Geboes, Karel ^a   Tousseyn, Thomas ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AUTOANTIGEN; BACULOVIRUS INHIBITOR OF APOPTOSIS PROTEIN REPEAT CONTAINING PROTEIN 3; CASPASE; CASPASE RECRUITMENT DOMAIN PROTEIN 11; CELL MEMBRANE PROTEIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; FORKHEAD TRANSCRIPTION FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PARACASPASE; PROTEIN BCL 10; TRANSCRIPTION FACTOR FOXP1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; BIRC3 PROTEIN, HUMAN; FOXP1 PROTEIN, HUMAN; ONCOPROTEIN; RELB PROTEIN, HUMAN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR RELB;

ANEUPLOIDY; BACTERIAL VIRULENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 12P; CHROMOSOME 13P; CHROMOSOME 21Q; CHROMOSOME 22P; CHROMOSOME DISORDER; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 3; CHRONIC INFLAMMATION; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE FREE SURVIVAL; ERADICATION THERAPY; GASTRITIS; GASTROENTERITIS; GASTROSCOPY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC DISORDER; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MALIGNANT TRANSFORMATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; STOMACH BIOPSY; STOMACH CARCINOGENESIS; STOMACH LYMPHOMA; SURVIVAL RATE; SURVIVAL TIME; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HELICOBACTER PYLORI; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOMA, B-CELL, MARGINAL ZONE; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STOMACH MUCOSA; STOMACH NEOPLASMS;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELB; TRANSLOCATION, GENETIC;

EID: 77953556367     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.58     Document Type: Review

References (117)

1. Martin, F. & Kearney, J. F. Marginal-zone B cells. Nat. Rev. Immunol. 2, 323-335 (2002).
2. Pillai, S., Cariappa, A. & Moran, S. T. Marginal zone B cells. Annu. Rev. Immunol. 23, 161-196 (2005).
3. Brigden, M. L. & Pattullo, A. L. Prevention and management of overwhelming postsplenectomy infection-an update. Crit. Care Med. 27, 836-842 (1999).
4. Kruschinski, C., Zidan, M., Debertin, A. S., von Horsten, S. & Pabst, R. Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum. Pathol. 35, 113-121 (2004).
5. Jaffe, e., Harris, N., Stein, H. & vardiman, J. World Health Organization Classification of Tumors: Pathology and Genetics: Tumors of Hemopoietic and Lymphoid Tissues (iARC, Lyon, 2008).
6. De Re, v. et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type ii cryoglobulinemia. Blood 96, 3578-3584 (2000).
7. Ferreri, A. J. M., Dolcetti, R., Magnino, S., Doglioni, C. & Ponzoni, P. Chlamydial infection: the link with ocular adnexal lymphomas. Nat. Rev. Clin. Oncol. 6, 658-669 (2009).
8. Lecuit, M. et al. immunoproliferative small intestinal disease associated with Campylobacter jejuni. N. Engl. J. Med. 350, 239-248 (2004). (Pubitemid 38067636)
9. Roggero, e. et al. eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum. Pathol. 31, 263-268 (2000).
10. Stefanovic, A. & Lossos, i. S. extranodal marginal zone lymphoma of the ocular adnexa. Blood 114, 501-510 (2009).
11. Thieblemont, C. et al. Primary thyroid lymphoma is a heterogeneous disease. J. Clin. Endocrinol. Met. 87, 105-111 (2002).
12. wotherspoon, A. C., Ortizhidalgo, C., Falzon, M. R. & isaacson, P. G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175-1176 (1991).
13. Zucca, e. et al. Prevalence of Helicobacter pylori and hepatitis C virus infections among non- Hodgkin's lymphoma patients in southern Switzerland. Hematologica 85, 147-153 (2000).
14. Coussens, L. M. & werb, Z. inflammation and cancer. Nature 420, 860-867 (2002).
15. Goossens, T., Klein, U. & Kuppers, R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc. Natl Acad. Sci. USA 95, 2463-2468 (1998).
16. Bonizzi, G. & Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288 (2004).
17. Ruefli-Brasse, A. A., French, D. M. & Dixit, v. M. Regulation of NF-κB-dependent lymphocyte activation and development by paracaspase. Science 302, 1581-1584 (2003).
18. Siebenlist, U., Brown, K. & Claudio, e. Control of lymphocyte development by nuclear factor B. Nat. Rev. Immunol. 5, 435-445 (2005).
19. Packham, G. The role of NF-κB in lymphoid malignancies. Br. J. Haematol. 143, 3-15 (2008).
20. Oh, S. Y. et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am. J. Hematol. 82, 446-452 (2007).
21. Zucca, e. et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101, 2489-2495 (2003). (Pubitemid 36857603)
22. Fischbach, w. et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology 119, 1191-1202 (2000).
23. Barth, T. F. e. et al. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (Gi) tract are blastic variants of Gi marginal zone lymphoma. J. Pathol. 211, 305-313 (2007).
24. Cogliatti, S. B. et al. Primary B-cell gastric lymphoma-a clinicopathological study of 145 patients. Gastroenterology 101, 1159-1170 (1991).
25. Thieblemont, C. et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95, 802-806 (2000).
26. Radaszkiewicz, T., Dragosics, B. & Bauer, P. Gastrointestinal malignant-lymphomas of the mucosa-associated lymphoid tissue-factors relevant to prognosis. Gastroenterology 102, 1628-1638 (1992).
27. Koch, P. et al. Primary gastrointestinal non- Hodgkin's lymphoma: ii. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German multicenter study GiT NHL 01/92. J. Clin. Oncol. 19, 3874-3883 (2001).
28. Koch, P. et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German Multicenter Study (GiT NHL 02/96). J. Clin. Oncol. 23, 7050-7059 (2005).
29. Craig, v. et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 115, 581-591 (2010).
30. Parsonnet, J. et al. Helicobacter pylori infection and gastric lymphoma. N. Engl. J. Med. 330, 1267-1271 (1994). (Pubitemid 24129959)
31. eck, M. et al. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 112, 1482-1486 (1997).
32. Doglioni, C., wotherspoon, A. C., Moschini, A., Deboni, M. & isaacson, P. G. High incidence of primary gastric lymphoma in northeastern italy. Lancet 339, 834-835 (1992).
33. Hussell, T., isaacson, P. G., Crabtree, J. e. & Spencer, J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342, 571-574 (1993).
34. Fischbach, w., Goebeler-Kolve, M. e., Dragosics, B., Greiner, A. & Stolte, M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 53, 34-37 (2004).
35. wundisch, T. et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J. Clin. Oncol. 23, 8018-8024 (2005).
36. O'Rourke, J. L. Gene expression profiling in Helicobacter-induced MALT lymphoma with reference to antigen drive and protective immunization. J. Gastroenterol. Hepatol. 23, S151-S156 (2008).
37. DeJong, D. et al. Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am. J. Clin. Pathol. 106, 670-675 (1996).
38. Hellmig, S. et al. Germline variations of the MALT1 gene as risk factors in the development of primary gastric B-cell lymphoma. Eur. J. Cancer 45, 1865-1870 (2009).
39. Hussell, T., isaacson, P. G., Crabtree, J. e., Dogan, A. & Spencer, J. immunoglobulin specificity of low-grade B-cell gastrointestinal lymphoma of mucosa-associated lymphoidtissue (MALT) type. Am. J. Pathol. 142, 285-292 (1993).
40. Morgner, A. et al. Helicobacter heilmanniiassociated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 118, 821-828 (2000).
41. Baens, M., Steyls, A., Geboes, K., Marynen, P. & wolf-Peeters, C. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am. J. Pathol. 156, 1433-1439 (2000).
42. Streubel, B. et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101, 2335-2339 (2003).
43. willis, T. G. et al. Bcl-10 is involved in t(1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96, 35-45 (1999).
44. wlodarska, i. et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19, 1299-1305 (2005).
45. Muller-Hermelink, H. K. Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas: marginal zone lymphomas. Hum. Pathol. 34, 336-340 (2003).
46. Starostik, P. et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 99, 3-9 (2002).
47. Fischbach, w. et al. S3 guideline Helicobacter pylori and gastroduodenal ulcer disease. Z. Gastroenterol. 47, 68-102 (2009).
48. Ye, H. T. et al. variable frequencies of t(11;18) (q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 102, 1012-1018 (2003).
49. Streubel, B. et al. variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18, 1722-1726 (2004).
50. Ye, H. T. et al. variable frequencies of t(11;18) (q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 102, 1012-1018 (2003).
51. Dierlamm, J. et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601-3609 (1999).
52. Roy, N. et al. The c-iAP-1 and c-iAP-2 proteins are direct inhibitors of specific caspases. Blood 90, 2645 (1997).
53. Uren, A. G. et al. identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell 6, 961-967 (2000).
54. Remstein, e. D., James, C. D. & Kurtin, P. J. incidence and subtype specificity of AP12- MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am. J. Pathol. 156, 1183-1188 (2000).
55. Motegi, M. et al. APi2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am. J. Pathol. 156, 807-812 (2000).
56. Kalla, J. et al. Heterogeneity of the AP12-MALT1 gene rearrangement in MALT-type lymphoma. Leukemia 14, 1967-1974 (2000).
57. Liu, H. X. et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear Bcl-10. Blood 98, 1182-1187 (2001).
58. Sagaert, X. et al. Comparative expressed sequence hybridization studies of t(11;18) (q21;q21)-positive and -negative gastric MALT lymphomas reveal both unique and overlapping gene programs. Mod. Pathol. 23, 458-469 (2010).
59. Alpen, B. et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 95, 4014-4015 (2000).
60. Liu, H. X. et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357, 39-40 (2001).
61. Sugiyama, T. et al. APi2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 120, 1884-1885 (2001).
62. Zullo, A. et al. effects of Helicobacter pylori eradication on early stage gastric mucosaassociated lymphoid tissue lymphoma. Clin. Gastroenterol. Hepatol. 8, 105-110 (2010).
63. Toracchio, S. et al. Translocation t(11;18) (q21;q21) in gastric B-cell lymphomas. Cancer Sci. 100, 881-887 (2009).
64. Sagaert, X., Laurent, M., Baens, M., wlodarska, i. & De wolf-Peeters, C. MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of Bcl-10 in the tumor cells. Mod. Pathol. 19, 225-232 (2006).
65. Streubel, B., vinatzer, U., Lamprecht, A., Raderer, M. & Chott, A. T(3;4)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19, 652-658 (2005).
66. Remstein, e. D., Kurtin, P. J., einerson, R. R., Paternoster, S. F. & Dewald, G. w. Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1. Leukemia 18, 156-160 (2004).
67. wotherspoon, A. C., Pan, L. X., Diss, T. C. & isaacson, P. G. Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet. Cytogenet. 58, 35-38 (1992).
68. Achuthan, R. et al. Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma. Genes Chromosomes Cancer 29, 347-349 (2000).
69. Ye, H. T. et al. Bcl-10 expression in normal and neoplastic lymphoid tissue-nuclear localization in MALT lymphoma. Am. J. Pathol. 157, 1147-1154 (2000).
70. Thome, M. CARMA1, Bcl-10 and MALT1 in lymphocyte development and activation. Nat. Rev. Immunol. 4, 348-359 (2004).
71. Sagaert, X. et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J. Clin. Oncol. 24, 2490-2497 (2006).
72. Haralambieva, e. et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 20, 1300-1303 (2006).
73. Banham, A. H. et al. expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 11, 1065-1072 (2005).
74. Barrans, S. L., Fenton, J. A. L., Banham, A., Owen, R. G. & Jack, A. S. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104, 2933-2935 (2004).
75. Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-282 (2004).
76. Han, S. L. et al. FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig. Surg. 26, 156-162 (2009).
77. Banham, A. H. et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 61, 8820-8829 (2001).
78. Hu, H. et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat. Immunol. 7, 819-826 (2006).
79. Barth, T. F. e. et al. Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer 31, 316-325 (2001).
80. Zhou, Y. P. et al. Distinct comparative genomic hybridisation profiles in gastric mucosaassociated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). Br. J. Haematol. 133, 35-42 (2006).
81. Ferreira, B. et al. Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Hematologica 93, 670-679 (2008).
82. Fukuhara, N. et al. Chromosomal imbalances are associated with outcome of Helicobacter pylori eradication in t(11;18)(q21;q21)-negative gastric mucosa-associated lymphoid tissue lymphomas. Genes Chromosomes Cancer 46, 784-790 (2007).
83. Kondo, T. et al. Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int. J. Oncol. 35, 547-557 (2009).
84. Sinn, D. H., Kim, Y. H., Lee, e. J., Ko, Y. H. & Kim, K. M. Methylation and APi2/MALT1 fusion in colorectal extranodal marginal zone lymphoma. Mod. Pathol. 22, 314-320 (2009).
85. Belair, C., Darfeuille, F. & Staedel, C. Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship. Clin. Microbiol. Infect. 15, 806-812 (2009).
86. Zhang, Z. Y. et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab. Invest. 88, 1358-1366 (2008).
87. Jiang, J. M., Lee, e. J. & Schmittgen, T. D. increased expression of microRNA-155 in epstein-Barr virus transformed lymphoblastoid cell lines. Genes Chromosomes Cancer 45, 103-106 (2006).
88. Li, Q. T. & verma, i. M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
89. Pomerantz, J. L. & Baltimore, D. Two pathways to NF-κB. Mol. Cell. 10, 693-695 (2002).
90. Ohmae, T. et al. Helicobacter pylori activates NF-κB via the alternative pathway in B lymphocytes. J. Immunol. 175, 7162-7169 (2005).
91. Ruland, J. et al. Bcl-10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104, 33-42 (2001).
92. Ruland, J., Duncan, G. S., wakeham, A. & Mak, T. w. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 19, 749-758 (2003).
93. Ye, H. T. et al. MALT lymphoma with t(14;18) (q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J. Pathol. 205, 293-301 (2005).
94. Nakagawa, M. et al. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood 106, 4210-4216 (2005).
95. Gaide, O. et al. Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-κB activation. FEBS Lett. 496, 121-127 (2001).
96. Bertin, J. et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/ membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-κB. J. Biol. Chem. 276, 11877-11882 (2001).
97. Allister-Lucas, L. M. et al. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-κB induction. J. Biol. Chem. 276, 30589-30597 (2001).
98. Rawlings, D. J., Sommer, K. & Moreno- Garcia, M. e. The CARMA1 signalosome links the signaling machinery of adaptive and innate immunity in lymphocytes. Nat. Rev. Immunol. 6, 799-812 (2006).
99. Gaide, O. et al. CARMA1 is a critical lipid raftassociated regulator of TCR-induced NF-κB activation. Nat. Immunol. 3, 836-843 (2002).
100. wang, D. et al. CD3/CD28 co-stimulationinduced NF-κB activation is mediated by recruitment of protein kinase C-θ, Bcl10, and IκB kinase β to the immunological synapse through CARMA1. Mol. Cell. Biol. 24, 164-171 (2004).
101. Sun, L. J., Deng, L., ea, C. K., Xia, Z. P. & Chen, Z. J. J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate iKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14, 289-301 (2004).
102. Lucas, P. et al. Bcl10 and MALT1, independent targets of chromosomal translocation in MALT lymphoma, cooperate in a novel NF-κB signaling pathway. J. Biol. Chem. 276, 19012-19019 (2001).
103. Zhou, H. L., Du, M. Q. & Dixit, v. M. Constitutive NF-κB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7, 425-431 (2005).
104. Baens, M. et al. Selective expansion of marginal zone B cells in e?-APi2-MALT1 mice is linked to enhanced IκB kinase β polyubiquitination. Cancer Res. 66, 5270-5277 (2006).
105. Ho, L. et al. MALT1 and the APi2-MALT1 fusion act between CD40 and iKK and confer NF-κB-dependent proliferative advantage and resistance against Fas-induced cell death in B cells. Blood 105, 2891-2899 (2005).
106. Hosokawa, Y., Suzuki, H., Nakagawa, M., Lee, T. H. & Seto, M. AP12-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-κB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-κB activation. Biochem. Biophys. Res. Commun. 334, 51-60 (2005).
107. Coornaert, B. et al. T cell antigen receptor stimulation induces MALT1 paracaspasemediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9, 263-271 (2008).
108. Heyninck, K. & Beyaert, R. A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem. Sci. 30, 1-4 (2005).
109. Honma, K. et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 47, 1-7 (2008).
110. Honma, K. et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114, 2467-2475 (2009).
111. Novak, U. et al. The NF-κB negative regulator TNFAiP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. Blood 112, 116-117 (2008).
112. Zullo, A. et al. eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am. J. Gastroenterol. 104, 1932-1937 (2009).
113. Zucca, e. & Dreyling, M. Gastric marginal zone lymphoma of MALT type: eSMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19, 70-71 (2008).
114. Ferrucci, P. F. & Zucca, e. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br. J. Haematol. 136, 521-538 (2007).
115. Stathis, A. et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann. Oncol. 20, 1086-1093 (2009).
116. Fischbach, w. et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 56, 1685-1687 (2007).
117. Copie-Bergman, C. et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 52, 1656 (2003).